DOCSLIB.ORG

LIFE SCIENCE ACROSS the ØRESUND – a Survey of Transregional Commuters, Actors, Research and Investments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LIFE SCIENCE ACROSS the ØRESUND – a Survey of Transregional Commuters, Actors, Research and Investments LIFE SCIENCE ACROSS THE ØRESUND – a survey of transregional commuters, actors, research and investments 900 border commuters in Medicon Valley At least 20 Danish CEOs at companies in Skåne 13 Danish companies listed in Sweden since 2014 PREFACE The Danish-Swedish life science cluster that spans over the Øresund, Medicon Valley, is linked together by all of the engaged individuals who work at the universities, hospitals, research centres and all of the LIFE SCIENCE ACROSS THE ØRESUND companies in the region. As part of the Interreg-project Greater Copenhagen Life Science Analysis Initiative, – a survey of transregional commuters, actors, Øresundsinstituttet has surveyed networks, collaborations, investments, ownership and personal contacts research and investments in Medicon Valley. More than 900 people employed at companies in the life science cluster commute across the Øresund Strait, This analysis has been prepared by Øresundsinstituttet as part of the Interreg- most of them from Skåne to Danish companies such as Novo Nordisk, Ferring, LEO Pharma, Lundbeck and project Greater Copenhagen Life Science Analysis Initiative and was written by Genmab. The growing group of companies from Skåne – frequently small and listed in Sweden – is also hel- Jenny Andersson, Kristoffer Dahl Sørensen, Sofi Eriksson and Johan Wessman. ping itself to the generous offering of skilled business leaders schooled in the large life science companies across the strait in Denmark. Today, more than 20 life science companies in Skåne are headed by a Danish Project manager for analytics: Jenny Andersson CEO. Ultimately, in and around Copenhagen is where Medicon Valley’s largest life science companies are. Overall project manager: Johan Wessman The Danish system of large, foundation-owned companies means that power over the company remains in Denmark, even if it is publicly traded, and it also means that part of the company’s profits return to research Translation: Justina Bartoli and new startups via the foundations that own them. In Sweden, the focus is more on going public; since 2014, thirteen Danish life science companies have acted on the attraction to listing in Stockholm, and twelve Cover photo: News Øresund of them are still listed today. More than 25 companies are active on both sides of the Øresund – and this is no novel phenomenon. Already back in 1914, the then-Danish Løvens Kemiske Fabrik set up a Swedish sub- June 2021 sidiary in Helsingborg: Leo Läkemedel. The company has changed hands many times since then, and today it’s known as McNeil, and its manufacturing and development units are still in Helsingborg. GREATER COPENHAGEN LIFE SCIENCE ANALYSIS INITIATIVE is an EU-project aimed at increasing knowledge about the region’s life science cluster. The focus is on the There is nothing new about national rules and regulations making work across the strait more difficult despite demand for labourers, future expertise needs, and more. The project has received the proximity over the Øresund with the bridge connecting Copenhagen and Malmö and ferries shuttling funding through the EU-programme Interreg Öresund-Kattegatt-Skagerrak and will between Helsingborg and Helsingør. University grants are generally not allowed to cross borders, for example, continue until 30 June 2022. The project’s lead partner is Medicon Valley Alliance, and although a good collaboration means bilateral flow. Over the past six years, crossing the Øresund has become the partner is Øresundsinstituttet. Region Skåne and Region Zealand are co-funding even more difficult for us humans. The migration crisis, crime and now the coronavirus pandemic have led to the project. national decrees on border control and at times even partially closed the borders. At the same time, the border region is receiving support from Brussels via the EU-programme Interreg Öresund-Kattegat-Skagerrak. Since 2015, Interreg has granted nearly €47mn for joint border regional development projects in the life sciences. This analysis is part of one such project. After more than 50 interviews with players from Medicon Valley, we can draw several conclusions: MEDICON VALLEY is the bi-national life science • Personal contacts are of great consequence for the border regional development between Sweden cluster spanning eastern Denmark and the and Denmark. Skåne region of southern Sweden. Today, the Danish-Swedish region is marketed interna- • The national systems still have difficulty managing a border region. tionally with the name ‘Greater Copenhagen’, • The trans-Øresund exchange is extensive. Medicon Valley’s Danish and Swedish parts are tightly and its increasing population has reached interwoven by their people, capital, projects, research and affairs. more than four million residents. In Sweden, • There remains great potential to increase contacts across the Øresund. The Øresund is where the same geographical area is often called the Denmark’s and Sweden’s national life science strategies meet. Two neighbouring countries, both ‘Øresund Region’. successful in the life sciences, each an important trade partner for the other. The interviews in this report show that the actors who see great opportunities in expanding collaborations are very many. Copenhagen and Malmö, 22 June 2021 Johan Wessman CEO Øresundsinstituttet PHOTO: NEWS ØRESUND PHOTO: TABLE OF CONTENTS 1. Summary .................................................................. 6 2. Commuters and the labour market .......................... 12 3. Management ........................................................... 26 4. Research and education .......................................... 47 Focus: Diabetes ........................................................ 56 Focus: Oncology ....................................................... 68 Focus: Reproduction ................................................. 82 BioInnovation Institute 5. Transregional sector actors and activities ............... 90 6. Investments and listings ....................................... 110 7. Appendix ............................................................... 135 PHOTO: LEO PHARMA PHOTO: ABOUT ZEALAND AND SKÅNE When we refer to Zealand and Skåne in this report, we are generally referring to the following geographic classification: the Danish island Zealand, and the southern Swedish province Skåne. There are also public and administrative geographies. On the Danish side, the Capital Region of Denmark includes the capital city Copenhagen and the surrounding municipalities, up to northeast Zealand and including the island Bornholm. Region Zealand comprises the remaining parts of Zealand and islands such as Møn, Lolland and Falster. On the Swedish side of the Øresund, the province of Skåne is geographically equivalent to Region Skåne. Together, the three Danish and Swedish regions comprise the Øresund Region, whose population was 4.1 million at the end of 2020, with two-thirds living on the Danish side. The Medicon Valley cluster shares the geography of the Øresund Region. The term Greater Copenhagen is used as an inter- national place brand for the Danish-Swedish region, and it also designates a political collaboration that encompasses the three abovementioned regions as well as Region Halland. The Greater Copenhagen region has a population of 4.4 million. LEO Pharma Open Innovation. SUMMARY SUMMARY 10 HIGHLIGHTS FROM THE REPORT +20 At least 20 Danish CEOs/managing di- rectors work in large, medium-sized and small life science companies in Skåne. NEWS ØRESUND & CELLAVISION PHOTO: The number of Danish directors has MORE THAN 900 BORDER COMMUTERS risen since 2017. Read more on page 27. Søren Bregenholt, new CEO of Simon Østergaard, new Alligator Bioscience in Lund. CEO of CellaVision in Lund. The life science sector’s labour force moves back and forth across the Øresund Region. A total of over 900 border commuters were identified in the region. At least 800 people commute from Skåne EXCELLENT RESEARCH IN THE REGION to work at life science companies in Zealand. At NEWS ØRESUND PHOTO: least 100 commuters from Zealand were identified Cancer, diabetes and reproduction are three research areas of excellence in Medicon Valley. as working in the life science sector in Skåne. World-class research is conducted in all three, and there are multiple links across the strait. These figures are the result of extensive contact There are around 600 researchers in CANCER RESEARCH at the hospitals in Region Skåne, between Øresundsinstituttet and the companies Region Hovedstaden and Region Sjælland, and there is also extensive research at the universities, between 2020-2021. One often hears about highly in the industry and at the Danish Cancer Society’s research institute in Copenhagen. Within cancer educated workers who are active across the Øre- research, it is relatively common for researchers and research groups to collaborate across the Examples of life science com- Number of border sund. Novo Nordisk is the Medicon Valley company panies in Zealand with border commuters from strait, but researchers call for more structural collaboration. with the largest number of border commuters. commuters from Sweden Sweden DIABETES RESEARCH has strong historical links to the 200 people travel from Sweden across the Øre- Novo Nordisk A/S 206 Øresund Region, as the predecessor to today’s Novo Nordisk sund to work at the company in Denmark. was founded in Copenhagen in 1923. Today, research centres Ferring Pharmaceuticals A/S 110 on both sides of the Øresund bring together diabetes research, LEO
Load more

Recommended publications
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • The Confusions in Nordic ESG Ratings
    Rating Objectivity: The Confusions in Nordic ESG Ratings ESG Ratings Subjectivity and its Consequences MASTER THESIS WITHIN: Business Administration NUMBER OF CREDITS: 30 ECTS PROGRAM OF STUDY: Civilekonom AUTHOR: John Rydholm & Samuel Schultzberg Bagge TUTOR: Fredrik Hansen & Toni Duras JÖNKÖPING May 2020 Master Thesis within Business Administration Title: Rating Objectivity: The Confusions in Nordic ESG Ratings - ESG Ratings Subjectivity and its Consequences Authors: John Rydholm, Samuel Schultzberg Bagge Tutors: Fredrik Hansen, Toni Duras Date: May 2020 Key terms: ESG, CSR, Ratings, Rating agencies, MSCI, Thomson Reuters, Sustainalytics, RobecoSAM Abstract: Environmental, Social and Governance measurements have significantly increased in usage due to growing concerns for environmental and sustainability problems in today’s world. However, with no commonly agreed-upon criteria for ESG ratings, the scoring measure creates confusion both at the investor and company level. Besides, ESG agencies have different processes and parameters for measuring ESG compliance, which contributes to the problem. The study examines four ESG rating agencies’ rating models and ESG scores to get a better understanding of deviations in ESG scores among Nordic companies. By also studying the correlation amongst ESG scores and market capitalizations in firms, the paper hopes to shed light on if any relationships exist between them. Our results show that the four major ESG raters in the study showed a weak to a non-significant correlation against each other. The maximum correlation found was 0.419 between Thomson Reuters and MSCI. RobecoSAM and MSCI showed the lowest significant correlation at 0.291. Sustainalytics was detected not to show any significant correlation with the other raters.
    [Show full text]
  • LIFE SCIENCE in SKÅNE – a Survey of Companies in the Sector
    LIFE SCIENCE IN SKÅNE – a survey of companies in the sector 426 companies 7 500 employees Medtech largest subsector Half of companies are located in science parks LIFE SCIENCE IN SKÅNE – a survey of companies in the sector PREFACE This analysis has been prepared by Øresundsinstituttet as part of the Interreg- There are 426 life science enterprises in Skåne, and together they employ 7 500 people in the region. That is around 1 500 more than the number of people employed by the same compa- project Greater Copenhagen Life Science Analysis Initiative and was written by nies five years ago. In the interim, 92 new life science enterprises have emerged in Skåne. Kristoffer Dahl Sørensen, Sofi Eriksson, Camilla Neve Lieknins and Emil Persson. More than half of Skåne’s life science businesses are based in science parks, and medtech is the largest subsector in the region: these are several of the main results of the survey of Project manager for analytics: Jenny Andersson companies presented in this report. In addition, Skåne’s life science businesses responded to Overall project manager: Johan Wessman questions about their needs for new staff and for new expertise in the future. It emerged that the primary need is for more competences in STEM, as well as sales and marketing. Translation: Justina Bartoli The coronavirus pandemic has changed the situations of many businesses, but the life Cover photo: News Øresund science sector appears to be one of the sectors to have weathered the crisis well to date. This is also apparent in Skåne; this spring, around 100 of Skåne’s life science companies November 2020 answered questions about whether the coronavirus pandemic had made it necessary for them to dismiss staff members.
    [Show full text]
  • 84. Møde Private Aktører Samt Gebyrfinansiering Af Visse Af Opgaverne))
    Torsdag den 26. marts 2020 (D) 1 Lovforslag nr. L 147 (Forslag til lov om ændring af lov om planteny‐ heder og lov om planter og plantesundhed m.v. (Opgaver i forbindel‐ se med sortslistegodkendelse og certificering, herunder delegation til 84. møde private aktører samt gebyrfinansiering af visse af opgaverne)). Torsdag den 26. marts 2020 kl. 10.00 Udlændinge- og integrationsministeren (Mattias Tesfaye): Dagsorden Lovforslag nr. L 148 (Forslag til lov om ændring af udlændingelo‐ ven. (Serviceeftersyn af reglerne for ulønnet frivilligt arbejde). 1) Eventuelt: 2. behandling af lovforslag nr. L 145: Forslag til lov om ændring af lov om en rejsegarantifond. (Udvidet Erhvervsministeren (Simon Kollerup): dækningsområde for Rejsegarantifonden i ekstraordinære situatio‐ ner). Lovforslag nr. L 149 (Forslag til lov om ændring af lov om for‐ Af erhvervsministeren (Simon Kollerup). brugslånsvirksomheder, lov om markedsføring og lov om finansiel (Fremsættelse 24.03.2020. 1. behandling 24.03.2020. Betænkning virksomhed. (Opgør med kviklån m.v.)). 25.03.2020). Justitsministeren (Nick Hækkerup): 2) Eventuelt: 2. behandling af lovforslag nr. L 142: Forslag til lov om ændring af lov om arbejdsløshedsforsikring m.v. Lovforslag nr. L 150 (Forslag til lov om ændring af lov om fuld‐ (Perioder, der ses bort fra ved forbrug af dagpenge m.v.) byrdelse af straf m.v. og retsplejeloven. (Adgang til sociale behand‐ Af beskæftigelsesministeren (Peter Hummelgaard). lingstilbud mod stofmisbrug for indsatte i kriminalforsorgens institu‐ (Fremsættelse 24.03.2020. 1. behandling 24.03.2020. Betænkning tioner m.v.)). 25.03.2020). Transportministeren (Benny Engelbrecht): 3) Eventuelt: 2. behandling af lovforslag nr. L 143: Forslag til lov om ændring af lov om sygedagpenge.
    [Show full text]
  • Novo Nordisk Annual Report 2012
    novo nordisk annual report 2012 Diabetes – an emergency in slow motion Strategy Sustainable growth is all about – can it be done? choice Insulin in Novo Nordisk’s performance in 2012 is a result of important decisions made in recent years a tablet – but there is more to the story – why is it so difficult? Contents Accomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlook Our business 15 Strategy is all about choice 20 Diabetes – an emergency Diabetes – an emergency in slow motion 20 in slow motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet – why is it so difficult? 28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets – one model 38 Sustainable growth – can it be done? 41 With every big opportunity comes a risk Governance, leadership and shares 44 Shares and capital structure The protein 46 Corporate governance 22 powerhouse 49 Remuneration 52 Board of Directors 54 Executive Management Financial, social and environmental statements 55 Consolidated financial, social and environmental statements 104 Financial statements of the parent company 109 Management’s statement and Auditor’s reports Additional information 112 More information Simple 28 injections 113 Product overview The Management review, as defined by the Danish Financial Statements Act (FSA), is found on pp 1–54 and 94. This Annual Report is published in both a Danish and an English language version. In the event of any discrepancies, the Danish version shall prevail. 1 Chairman of the Board of Directors Sten Scheibye at the Annual General Meeting in March 2012.
    [Show full text]
  • 99. Møde Per Larsen (KF) Onsdag Den 21
    Onsdag den 21. april 2021 (D) 1 (Spm. nr. S 1325). 4) Til sundhedsministeren af: 99. møde Per Larsen (KF) Onsdag den 21. april 2021 kl. 13.00 Hvad er ministerens holdning til, at den nye vaccinationsplan i ud‐ gangspunktet ikke sikrer yngre personer med f.eks. alvorlige eller kroniske sygdomme, som nu må vente med at blive vaccineret, da Dagsorden man er gået over til at vaccinere efter alder? (Spm. nr. S 1326). 1) Besvarelse af oversendte spørgsmål til ministrene (spørgetid). (Se nedenfor). 5) Til sundhedsministeren af: Pernille Skipper (EL) 2) 1. behandling af lovforslag nr. L 194: Hvad kan ministeren oplyse om konsekvenserne for landets fødegan‐ Forslag til lov om ændring af lov om almene boliger m.v., lov om le‐ ge, hvis hver fjerde jordemoder vælger ikke at tage arbejde i den je af almene boliger og lov om leje. (Tidligere hårde ghettoområder, offentlige sektor, jf. artiklen »Mere end hver fjerde af landets jorde‐ som er omfattet af en udviklingsplan). mødre nægter at arbejde i den offentlige sektor« fra Berlingske den Af indenrigs- og boligministeren (Kaare Dybvad Bek). 8. april 2021, og hvad vil ministeren gøre for at forhindre, at et stort (Fremsættelse 24.03.2021). antal jordemødre fravælger at arbejde på landets fødegange på grund af de nuværende løn- og arbejdsvilkår? 3) Forhandling om redegørelse nr. R 13: (Spm. nr. S 1334). Udenrigsministerens redegørelse om udvalgte internationale organi‐ sationer (OSCE, Europarådet og Østersørådet). 6) Til sundhedsministeren af: (Anmeldelse 10.03.2021. Redegørelse givet 10.03.2021. Meddelelse Peter Juel-Jensen (V) om forhandling 10.03.2021).
    [Show full text]
  • ERSA 2010 Sanchez Et Al Medicon Valley
    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Carreira, Maria Del Carmen Sanchez; Deza, Xavier Vence; Marzábal, Óscar Rodil Conference Paper Strategic innovation policies and the emergence of new clusters: the comparative experience of the binational Medicon Valley 50th Congress of the European Regional Science Association: "Sustainable Regional Growth and Development in the Creative Knowledge Economy", 19-23 August 2010, Jönköping, Sweden Provided in Cooperation with: European Regional Science Association (ERSA) Suggested Citation: Carreira, Maria Del Carmen Sanchez; Deza, Xavier Vence; Marzábal, Óscar Rodil (2010) : Strategic innovation policies and the emergence of new clusters: the comparative experience of the binational Medicon Valley, 50th Congress of the European Regional Science Association: "Sustainable Regional Growth and Development in the Creative Knowledge Economy", 19-23 August 2010, Jönköping, Sweden, European Regional Science Association (ERSA), Louvain-la-Neuve This Version is available at: http://hdl.handle.net/10419/119144 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich
    [Show full text]
  • Company Note
    Meet - the Equity Research - management event in managementBoston in event Investment Research Company update 8 February 2017 Novo Nordisk Buy (Unchanged) Pharmaceuticals, Denmark Meet-the-management event in Boston Key data On the day of the FY release, there was much focus on risks due to the changed Price (DKK)* 234 Target price, 12 mth (DKK) † 300 guidance range. The meet-the-management event in Boston on Tuesday had Market cap (DKKm) 606,998 more focus on opportunities. Our impression is that management is talking more Market cap (EURm) 81,652 towards the high end of guidance but that the low end was changed if something Reuters NOVOb.CO unexpected (not very likely) should occur. We keep our DKK300 12M TP and Buy. Bloomberg NOVOB DC No. of shares (m) 2,599.6 Clearer message. Novo has had time to digest how its FY release was received Net debt (current Y/E) (m) -14,353 and its communication has become clearer. The EBIT guidance of -2% to +3% Free float 73.0% Avg. daily vol, 12M (000) 3,376.6 growth in 2017 includes a 4% headwind from Vagifem generics and a tough Norditropin comp. Adjusting for this implies 2-7% growth, which makes it Price performance 400 380 comfortable to deliver 5%-plus after 2017. Cost savings in 2017 from layoffs in 2016 360 340 come to DKK1bn and Novo is set to save a further DKK500m from procurements 320 300 280 in 2017 (and 2018) – savings that have been invested in other parts of Novo. 260 240 220 US.
    [Show full text]
  • State of Medicon Valley 2018
    A COMPARISON OF SCIENTIFIC PUBLICATIONS IN 10 EUROPEAN LIFE SCIENCE CLUSTERS STOCKHOLM-UPPSALA SCOTLAND MEDICON VALLEY NETHERLANDS LONDON-CAMBRIDGE-OXFORD FLANDERS ÎLE DE FRANCE BIOVALLEY MUNICH ZURICH STATE OF MEDICON VALLEY 2018 An Analysis of Life Science in Greater Copenhagen PREFACE Medicon Valley is in a period of transition. The life science sector has been the region’s growth motor, even through the darkest years of the economic crisis. But now is no time to rest on laurels. The sector is facing new research breakthroughs in everything from personalised medicine to biopharmaceuticals and gene therapy. The dividing lines to other sectors are being dissolved with new digital solutions and arti- ficial intelligence that in part facilitate diagnostics and in part give patients increased control over their care. One of the most important foundations for the creation of a competitive life science cluster is the access to – and the emergence of – internationally leading university environments and research institutions. For this reason, we have commissioned a unique comparison of Europe’s ten most influential life science clusters, based on scientific publication volume in the life sciences, from the Dutch research institute CWTS at Leiden University. We’re happy to report that the percentual increase in scientific publications in the life sciences is greater in Medicon Valley than in any other cluster in Europe’s other Top Ten. Calculated according to the number of publications, the region’s placement is firmly in the middle of the list, at the top of which is the life science cluster in Lon- STATE OF MEDICON VALLEY 2018 don-Cambridge-Oxford.
    [Show full text]
  • Lundamats III Strategy for a Sustainable Transport System in Lund Municipality Foreword Contents
    LUNDAMATS III Strategy for a sustainable transport system in Lund Municipality Foreword Contents For a long time Lund Municipality has been working success- Page fully to take its transport system in an ever more sustainable 5 Why LundaMaTs III? direction. This work has attracted much attention at both People, traffic and sustainability in Lund national and international level. On many occasions the 6 Municipality has received awards for its work. 8 Future trends Since LundaMaTs II was adopted in 2006, the conditions 10 The transport system of the future for traffic and urban planning in Lund have changed. Lund 12 Six focus areas for a more sustainable is expanding, and its growing population and number of transport system in Lund businesses require more efficient use of its land and transport. 14 LundaMaTs’ targets The change in these conditions means that our approach and 15 LundaMaTs taken in context focus need updating in order to achieve long-term sustain- 16 Focus area 1 – Development of the villages able social development. LundaMaTs was therefore updated 18 Focus area 2 – A vibrant city centre during the autumn of 2013 and the winter of 2014, and on 7 May 2014 the City Council took the decision to adopt 20 Focus area 3 – Business transport LundaMaTs III. 22 Focus area 4 – Regional commuting LundaMaTs III will give our work clear direction over 24 Focus area 5 – A growing Lund the coming years and create favourable conditions for deve- 26 Focus area 6 – Innovative Lund lopment whereby the transport system will help ensure a better quality of life for all the residents, visitors and business operators in Lund.
    [Show full text]
  • Letter Without Tagline
    CH D Press release DONGBAO TO ACQUIRE FERRING’S MALMÖ MANUFACTURING OPERATION Saint Prex, Switzerland and Shanghai, China, Friday 17 November, 2006 – Ferring Pharmaceuticals and Shanghai Dongbao Biopharmaceutical Company announced today the signing of an agreement by which Dongbao Biopharmaceutical will purchase Ferring’s manufacturing operation at Malmö in Sweden. Earlier this year, Ferring informed staff of its plan to cease manufacturing at Malmö by the end of March 2008. However, the acquisition by Dongbao Biopharmaceutical has secured the jobs of around 50 members of staff. The agreement will become effective on 1 January, 2007. “From the very beginning, our aim has been to find a solution which would maintain the Malmö production site,” commented Ferring Pharmaceuticals Chief Operating Officer, Michel Pettigrew. “This agreement is a boost for the local community and has secured the long-term future of the factory for around 50 employees, whose experience will be invaluable to Dongbao Biopharmaceutical.” “We see great potential for the manufacturing centre at Malmö,” added Dr George Li, President of Dongbao Biopharmaceutical. “The site is technically very developed and the current team, who will be an important part of our future business development, offer a lot of knowledge and competencies.” Ends Ferring International Center S.A., Chemin de la Vergognausaz 50, 1162 Saint‐Prex, Switzerland Tel: +41 58 301 00 00, Fax: +41 58 301 00 10, www.ferring.com CH About Ferring: Ferring is a Swiss-based research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology.
    [Show full text]
  • Triptorelin Pamoate (Subcutaneous Injection) for Prostate Cancer NIHRIO (HSRIC) ID: 20540 NICE ID: 9841
    NIHR Innovation Observatory Evidence Briefing: May 2018 Triptorelin pamoate (subcutaneous injection) for prostate cancer NIHRIO (HSRIC) ID: 20540 NICE ID: 9841 LAY SUMMARY Prostate cancer is cancer of the prostate gland (a small organ in a man’s pelvis) and is the second most common cancer in the UK. There are three stages: localised, locally‐advanced and advanced (or metastatic) prostate cancer. The symptoms of prostate cancer may vary depending on the stage of cancer but can include pain, tiredness, problems emptying the bladder and the bowels. About half of men diagnosed with locally‐advanced prostate cancer will see their cancer spread to other body organs (i.e. becoming metastatic). Triptorelin is being developed as an injection under the skin (subcutaneous) for the treatment of locally advanced or metastatic prostate cancer. It is already marketed for this condition but is given by injection deep into the muscles (intramuscular). Triptorelin is an artificial analogue of natural gonadotropin‐releasing hormone that acts to slowly reduce the level of testosterone in the body. The first administration of triptorelin stimulates an increase in testosterone levels but prolonged administration leads to a fall in plasma testosterone or oestradiol to castrate levels which is maintained for as long as the product is administered. Triptorelin as a subcutaneous injection formulation has the potential advantage of improved safety and local tolerability when compared to intramuscular injection formulation. This briefing reflects the evidence available at the time of writing. A version of the briefing was sent to the company for a factual accuracy check. The company was available to provide comment.
    [Show full text]